U.S. markets open in 5 hours
  • S&P Futures

    4,547.00
    +38.50 (+0.85%)
     
  • Dow Futures

    34,329.00
    +327.00 (+0.96%)
     
  • Nasdaq Futures

    15,983.00
    +113.25 (+0.71%)
     
  • Russell 2000 Futures

    2,176.50
    +30.20 (+1.41%)
     
  • Crude Oil

    66.76
    +1.19 (+1.81%)
     
  • Gold

    1,771.50
    -12.80 (-0.72%)
     
  • Silver

    22.35
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1322
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    28.00
    +0.81 (+2.98%)
     
  • GBP/USD

    1.3305
    +0.0027 (+0.20%)
     
  • USD/JPY

    113.2360
    +0.4560 (+0.40%)
     
  • BTC-USD

    56,945.74
    -77.07 (-0.14%)
     
  • CMC Crypto 200

    1,451.16
    -17.92 (-1.22%)
     
  • FTSE 100

    7,132.42
    -36.26 (-0.51%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will participate in a Fireside Chat and host one-on-one investor meetings during the 4th Annual Evercore ISI HealthCONx Conference, taking place November 30-December 2, 2021. Details for the Fireside Chat can be found below:

4th Annual Evercore ISI HealthCONx Conference

Date:

Tuesday, November 30, 2021

Time:

4:20pm ET

Webcast:

Click here

A replay of the Fireside Chat will also be available on BeyondSpring’s website on the Events & Presentations page for 30 days following the conclusion of the conference.

About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset, plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), is being developed as a “pipeline in a drug” in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). It is filed for approval and has received breakthrough designation and Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) with a PDUFA date of November 30, 2021 in the U.S. In the DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, the plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2nd/3rd line NSCLC (EGFR wild type). Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com

Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
darren@lifescicomms.com